Head and Neck Cancer
Clinical research in recurrent or metastatic squamous cell carcinoma of the head and neck with an emphasis on PD-L1-positive disease and first-line immunotherapy combinations.
- Immune checkpoint blockade
- LAG-3 and TIM-3 targeting
- Metastatic solid tumours
The focus includes combination immuno-oncology strategies for advanced head and neck malignancies.
Paediatric Haematologic Malignancies
Research activity also covers children with advanced leukaemias, including chronic myeloid leukaemia that is resistant or intolerant to prior BCR-ABL-targeted therapy.
- Chronic myeloid leukaemia
- Tyrosine kinase inhibitor resistance
- Paediatric oncology
These studies reflect interest in targeted treatment options for paediatric blood cancers.
Paediatric Solid Tumours
Clinical development extends to selected advanced solid tumours in paediatric participants, including settings where disease is recurrent or refractory.
- Advanced solid tumours
- Recurrent disease
- Refractory disease
This area includes oncology research spanning both haematologic and solid tumour indications in children.
Recurrent or Refractory Cancers
The sponsor funds studies in recurrent or refractory leukaemias, lymphomas, and solid tumours, supporting research across difficult-to-treat advanced malignancies.
- Leukaemias
- Lymphomas
- Advanced malignancies
Interest in this field spans oncology with both targeted therapy and immunotherapy approaches.
